Category Archives: Jim’s Corner

Physician Payments Sunshine Act: Collaboration Key for Doctors & Biopharmas

Jim Greenwood

In a letter to the editor on USA Today, BIO CEO Jim Greenwood and John J. Castellani, president of PhRMA, write that context must accompany the data being provided under the Physician Payments Sunshine Act: “Discovery of new and improved medicines would be impossible without collaborations between physicians and biopharmaceutical companies. Consider ongoing research and clinical trials that not only make medicines possible, but also help our understanding of disease. Biopharmaceutical professionals help physicians stay Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Biotech Investors, Emerging Companies Bullish On 2014

Jim Greenwood

The 16th BIO CEO & Investor Conference is off to a great start. This event has truly grown into a must attend for emerging companies and investors. This year, we have more than 1,300 participants, including more than 850 investors. In addition, we have helped to set up more than 1,700 partnering meetings for participants over the course of the conference. Our world-class partnering system, and the opportunity to hear from key industry leaders, is Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

FDA Week: For Biologics, A Name Isn’t Just A Name (Jim Greenwood op-ed)

Jim Greenwood

What is in a name? Names help make medicinal products more easily distinguishable by doctors, pharmacists and patients. When you are talking about biologics, complex medicines that are manufactured using living organisms, and biosimilars, medicines that are similar to, but not the same as, innovator biologics, naming is a significant consideration. As a pathway for biosimilars approval is implemented, a clear priority should be to craft a naming convention that both contributes to patient safety Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Stable Policy Can Help Assure Unwavering Investment in U.S. Biofuels

Jim Greenwood

The Renewable Fuel Standard (RFS) is a unique federal policy that has, just as its bipartisan supporters intended, spurred major domestic and international investment in US biofuels production and it is essential to maintaining a growing market for second generation biofuels. That growing market helps attract investment to advanced biofuel companies who are trying to expand their infrastructure, scale up their production line, and improve their technology foundation. Unfortunately, the Environmental Protection Agency’s (EPA) recent Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Congress Passes Omnibus Spending Agreement

Jim Greenwood

This week, BIO President and CEO Jim Greenwood praised the Congress for passing the fundingbill for fiscal 2014, which would, among other things, allow the Food and Drug Administration (FDA) to access $85 million in user fees sequestered in 2013. In addition, BIO supports the agreement’s overall funding for: FDA, NIH, the biodefense enterprise; and improved program oversight of the important 340B program.  BIO also strongly supports the language in the bill providing the Department Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,